Navigation Links
AssureRx Adds New CEO
Date:6/9/2009

Experienced Executive to Lead Personalized Medicine Company in Next Phase of Growth

CINCINNATI, June 9 /PRNewswire/ -- AssureRx, a personalized medicine company, announced today that James S. Burns has joined the Mason-based company as its new President and CEO.

Burns comes to AssureRx with more than 30 years of executive experience in the strategic management of science and technology for pharmaceutical, diagnostic, and biotech companies. Most recently, he was president and CEO of Maryland-based EntreMed Inc., a public clinical-stage pharmaceuticals company developing drugs for the treatment of cancer and inflammatory diseases.

Previously, he was a co-founder and president of MedPointe Pharmaceuticals Inc., a specialty pharmaceuticals company that develops, markets, and sells branded prescription pharmaceuticals. He also was founder and managing director of MedPointe Capital Partners, a private equity firm that led the buyout of a New York Stock Exchange company to form MedPointe Pharmaceuticals.

Mr. Burns was also a founder, chairman, president and CEO of Osiris Therapeutics Inc., a public biotech company developing therapeutic stem-cell products for the regeneration of damaged or diseased tissues. Previously, he was a founding general partner of Healthcare Ventures LP, a venture capital partnership specializing in forming companies built around new pharmaceutical and biotechnology products; a group president at Becton Dickinson and Co.; and a partner at Booz Allen Hamilton, a global strategy and technology consulting firm.

"We are thrilled to have a person of Jim's caliber leading the company into the next phase of its growth. His depth and breadth of experience as CEO of successful early-stage health care companies po
'/>"/>

SOURCE AssureRx
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. AssureRx Adds VP of Sales and Marketing
2. AssureRx Closes Round of Funding to Commercialize Pharmacogenetic Test

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)... charge their cell phones and other personal elect...ry made by UC San Diego engineers could lead to ca...just this. , In recent research, published in ...fessor in the UCSD Department of Mechanical and Ae...ark Hoefer, have found that artificially introduce...
(Date:11/19/2009)...v. 19 Spherix Incorporat... for diabetes therapy, and a provider of technical...ement, biotechnology and pharmaceutical companies,... $6.3 million registered direct placement to insti...on stock and warrants to purchase up to 1,104,348 ...
(Date:11/19/2009)...mber 19 MONITORING FORCE GmbH,anno...Flibanserin in the,indication treatment-relevant l...for orphan drug status designation with the Europe...nesia is a complication of the mainstay,treatment ...me of those,affected, since it may be disabling fo...
(Date:11/19/2009)...ored by latest award for revolutionary hearing aid...vember 16, 2009 -- Popular Science Magazine has na...from InSound Medical a winner of its coveted Best ...nbsp;   Chosen from thousands of en...aring canal for up to four months while providing ...
Breaking Biology Technology:Nanotube defects equal better energy and storage systems 2Spherix Announces the Closing of $6.3 Million Registered Direct Offering 2Spherix Announces the Closing of $6.3 Million Registered Direct Offering 3MONITORING FORCE GmbH Requests Acknowledgment of Flibanserin as "Orphan Drug" 2Popular Science Awards Lyric “Invisible” Hearing Aid 2009 “Best of What's New” Award 2Popular Science Awards Lyric “Invisible” Hearing Aid 2009 “Best of What's New” Award 3
...tar,Therapeutics (Nasdaq: NKTR ) will announce it...rch 31, 2008 on Wednesday, May 7, 2008, after the,...n, president and chief,executive officer, will hos... Time (ET)., Investors can access the press relea... call through a link that is posted on the Investo...
... BTV8 vaccine released to supply Northern ...therlands, April 30 ,Intervet/Schering-Plough Anim...f Bovilis BTV8 vaccine against bluetongue to suppl...ombining after the acquisition in 2007 the,strengt...s not only the,world market leader in the producti...
... Squibb,Company (NYSE: BMY ) invites investors an... annual meeting with stockholders at 10 a.m. ET on...er and board items to be,transacted, senior execut...ess., For information on how to listen to the web...the Bristol-Myers Squibb website at, http://www.bm...
Other Biology Technology:Nektar to Announce Q1 2008 Financial Results on Wednesday, May 7, 2008, After Close of U.S.-Based Financial Markets 2Intervet/Schering-Plough Animal Health Outlines Strength of the Combination 2Intervet/Schering-Plough Animal Health Outlines Strength of the Combination 3
(Date:11/22/2009)...ch Centre, a partnership of the University of Brit...stal Health Research Institute, have uncovered new...lls die following a stroke, as well as a possible ...udy were recently published online in Nature Medi...ntinue to die even after blood flow has been resto...
(Date:11/20/2009)...ead studies about the health benefits of having a ...lar level, where amino acids known as cysteines ar...when paired up with other cysteines. , Now, rese...colleagues in Belgium, have discovered a new antio...research appears in the Nov. 20 issue of the journ...
(Date:11/20/2009)...09) Scientists from the Marine Biogeochemistry an...earch Laboratory (NRL) organized and led a team of... expedition to initiate methane hydrate exploratio...riation of sediment contribution to Arctic climate... Polar Sea as a research platform, three cross-she...
Breaking Biology News(10 mins):New understanding about mechanism for cell death after stroke leads to possible therapy 2Saving the single cysteine: New antioxidant system found 2International expedition investigates climate change, alternative fuels in Arctic 2Echo Therapeutics Initiates Clinical Study of its New One Piece Symphony 28TM 29 tCGM Biosensor in Type 1 and Type 2 Diabetic Patients 5982 1Echo Therapeutics Initiates Clinical Study of its New One Piece Symphony 28TM 29 tCGM Biosensor in Type 1 and Type 2 Diabetic Patients 5982 2Echo Therapeutics Initiates Clinical Study of its New One Piece Symphony 28TM 29 tCGM Biosensor in Type 1 and Type 2 Diabetic Patients 5982 3Sarnova Acquires Metropolitan Medical to Expand Portfolio of Specialty Health Care Products 5980 1Sarnova Acquires Metropolitan Medical to Expand Portfolio of Specialty Health Care Products 5980 2Sarnova Acquires Metropolitan Medical to Expand Portfolio of Specialty Health Care Products 5980 3Codexis Names Fernando Valle Research Fellow 5978 1Codexis Names Fernando Valle Research Fellow 5978 2
... Dust is one of several types of aerosols in the a...erstood ways. Dust scatters and absorbs solar radi...eract with cloud formation and other climate-affec...and Infrared Pathfinder Satellite Observation (CAL...erstanding of how clouds and aerosols interact. Li...
...eam at Worcester Polytechnic Institute (WPI) has r...onal Institutes of Health (NIH) for a project aime...skin cells into stem-like cells. If successful, th... straightforward method for replacing tissue lost ...tive diseases like diabetes and Parkinson,s. , Th...
...e cause of death in Europe and early diagnosis is ...hythm and electrical activity in real time using a...on about abnormalities and gives clues to the natu...-term monitoring inconvenient for patients as it ...onment for indeterminate periods of time. , Six ...
Other Biology News:AGU journal highlights -- Sept. 3, 2008 2AGU journal highlights -- Sept. 3, 2008 3AGU journal highlights -- Sept. 3, 2008 4AGU journal highlights -- Sept. 3, 2008 5AGU journal highlights -- Sept. 3, 2008 6AGU journal highlights -- Sept. 3, 2008 7NIH EUREKA award funds research at WPI aimed at turning adult skin cells into stem-like cells 2NIH EUREKA award funds research at WPI aimed at turning adult skin cells into stem-like cells 3NIH EUREKA award funds research at WPI aimed at turning adult skin cells into stem-like cells 4A home early warning system for cardiac patients 2
HeLa Cell Slide from ProSci, Inc
Anti-YAP, phospho (Ser127) Antibody, Unconjugated from Cell Signaling Technology
EL4 Cell Slide from ProSci, Inc
BALB/3T3 Cell Slide from ProSci, Inc
Biology Products: